Search
Atopic Dermatitis Paid Clinical Trials in Indiana
A listing of 16 Atopic Dermatitis clinical trials in Indiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 16
The state of Indiana currently has 16 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Featured Trial
Atopic Dermatitis (Eczema) Study (Ages 12 to 17)
Recruiting
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Atopic Dermatitis (Eczema) Study (Ages 12 to 17)
Recruiting
Featured Trial
Moderate to Severe Atopic Dermatitis Study
Recruiting
Conditions:
Atopic Dermatitis
Featured Trial
Atopic Dermatitis (Eczema) Study (Ages 18+)
Recruiting
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/19/2024
Locations: Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana +2 locations
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: DS Research, Clarksville, Indiana +3 locations
Conditions: Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
All
Ages:
Between 18 years and 63 years
Trial Updated:
06/19/2024
Locations: Dawes Fretzin, LLC /ID# 264534, Indianapolis, Indiana +1 locations
Conditions: Atopic Dermatitis
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.
The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: LEO Pharma Investigational Site, Plainfield, Indiana
Conditions: Atopic Dermatitis, Atopic Hand Eczema
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis.
The estimated duration is 15-35 days for screening and then up to approximately day 378 (last dose on day 280 + 98 days safety follow-up) for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/06/2024
Locations: DS Research, Clarksville, Indiana +1 locations
Conditions: Moderate to Severe Atopic Dermatitis
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
Recruiting
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: AnaptysBio Investigative Site 10-127, Clarksville, Indiana +2 locations
Conditions: Atopic Dermatitis Eczema
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
Recruiting
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses.
The trial will last up to 36 weeks... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2024
Locations: LEO investigational site, Indianapolis, Indiana +1 locations
Conditions: Atopic Dermatitis
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: Dawes Fretzin Clinical Research, Indianapolis, Indiana
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
This study is seeking participants who:
are 18 years of age or more.
Were confirmed to have AD at least 6 months ago.
Are not having an effective treatment result from medicines that are applied on skin for AD.
Are considered by their doctors to have moderate to severe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Southern Indiana Clinical Trials, New Albany, Indiana
Conditions: Atopic Dermatitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: Up0110 118, West Lafayette, Indiana
Conditions: Atopic Dermatitis
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group, Indianapolis, Indiana
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Dermatology Specialists Research Indiana, Clarksville, Indiana +1 locations
Conditions: Atopic Dermatitis
1 - 12 of 16